Search
Search Results
-
An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
BackgroundZoledronate, a bisphosphonate, is a potent first-line treatment for osteoporosis. It is also a preferred treatment for hypercalcemia...
-
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience
Bone metastases (BM) are a serious cancer complication, potentially causing substantial morbidity. Among the clinical issues related to BM, there is...
-
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
SummaryThis registry-based study of 3068 patients with osteoporosis compared the anti-fracture effectiveness of denosumab versus bisphosphonates....
-
Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study
PurposeThe aim of this study was to evaluate changes in hip geometry parameters following treatment with teriparatide (TPD), denosumab (Dmab) and...
-
Zoledronate treatment exerts sex-independent effects on bone and dental physicochemical properties in mice jaw necrosis
IntroductionBisphosphonate (BF) therapy is strongly related to the occurrence of medication-related osteonecrosis of the jaw (ONJ). However, no...
-
Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature
PurposeThis three-case report aims to highlight the ocular adverse effects induced by bisphosphonate therapy and to call clinicians’ attention.
... -
Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis
SummaryZoledronate could be contributing to the development of acute kidney injury in a small number of patients. Since estimated glomerular function...
-
Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate
IntroductionTo devise a precise and efficient tool for predicting the individualized risk of acute-phase response (APR) in bisphosphonate (BP)-naive...
-
Fluorescent risedronate analogue 800CW-pRIS improves tooth extraction-associated abnormal wound healing in zoledronate-treated mice
BackgroundBisphosphonate-related osteonecrosis of the jaw (BRONJ) is a rare but serious side effect of nitrogen-containing bisphosphonate drugs...
-
Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate
BackgroundSkeletal-related events (SREs) are related to morbidity and mortality in patients with bone metastatic prostate cancer, and preventive...
-
Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw
IntroductionOsteonecrosis of the jaw (ONJ) occurring after invasive dental treatment often adversely affects patients’ activities of daily living....
-
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
SummaryThis phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women...
-
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis
SummaryPostmenopausal patients with osteoporosis who have a recent fracture are at very high risk of fracture, and this study finds that stratified...
-
Clinicians’ views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study
BackgroundBisphosphonate medications, including alendronate, ibandronate and risedronate administered orally and zoledronate, administered...
-
Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
BackgroundBone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow...
-
Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial
BackgroundSkeletal-related events (SREs) are critical events for patients with bone metastasis from non-small cell lung cancer (NSCLC). Thus,...
-
Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk
PurposeFive strategies were recommended by the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE)...
-
Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate
BackgroundSkeletal-related events (SREs) are significant contributors to the morbidity and mortality in patients with bone metastasis from breast...
